Menu
Warning! You won't be able to use the quotation basket until you enable cookies in your Web browser.
Warning! Your Web browser is no longer supported. Please upgrade to a modern browser.

Practical Guide to Predictive Factor Testing in Lung Cancer

Overview

Per World Health Organization(WHO), 2014 Fact Sheet, cancer is a leading cause of death worldwide, accounting for 8.2 million deaths in 2012 (Globocan 2012, IARC ). The most common causes of cancer death are cancers:  lung (1.59 million deaths), liver (745 000 deaths), stomach (723 000 deaths), colorectal (694 000 deaths), breast (521 000 deaths), oesophageal cancer (400 000 deaths) (1).  According to the survey, lung cancer is the leading cause of death worldwide.  This presentation is an overview and a guide to lung cancer testing and the factors involved in testing.  A review of the lung cancer drug therapies will be discuss as well as the specimen and tumor types associated with the drug therapy.  A guide to developing testing algorithms for mutation screening and confirmatory testing will be discussed.   A comparable practical advantage and disadvantage to lung testing will be highlighted.  Finally, an appreciation for the economic impact of the various testing algorithms and significance importance of false positive or negative will be discussed.

Get Knowledge Pathway updates delivered directly to your inbox.

If you have viewed this educational webinar, training or tutorial on Knowledge Pathway and would like to apply for continuing education credits with your certifying organization, please download the form to assist you in adding self-reported educational credits to your transcript.

Apply for self-reported educational credits

References

Learning Objectives

  1. Understanding of which specimens and tumor types are appropriate for testing to determine eligibility for erlotinib, gefitinib, afatinib, crizotinib, or other emerging targeted therapies.
  2. Overview on how to develop testing algorithms for mutation screening and confirmatory testing for EGFR, ALK, ROS1, and other genes of importance in lung cancer.
  3. Review on how to compare practical advantages and disadvantages of immunohistochemistry, in-situ hybridization, and molecular approaches in testing for EGFR, ALK, ROS1, and other gene mutations.
  4. Possible appreciation of the economic impact of various testing algorithms and the significance of false positive or false negative testing results.

Leica Biosystems Knowledge Pathway content is subject to the Leica Biosystems website terms of use, available at: Legal Notice. The content, including webinars, training presentations and related materials is intended to provide general information regarding particular subjects of interest to health care professionals and is not intended to be, and should not be construed as, medical, regulatory or legal advice. The views and opinions expressed in any third-party content reflect the personal views and opinions of the speaker(s)/author(s) and do not necessarily represent or reflect the views or opinions of Leica Biosystems, its employees or agents. Any links contained in the content which provides access to third party resources or content is provided for convenience only.

For the use of any product, the applicable product documentation, including information guides, inserts and operation manuals should be consulted. Leica Biosystems and the editors hereby disclaim any liability arising directly or indirectly from the use of the content, including from any drugs, devices, techniques or procedures described in the content.

Copyright © 2020 Leica Biosystems division of Leica Microsystems, Inc. and its Leica Biosystems affiliates. All rights reserved. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.

Want us to feature your writing?

We are looking for more great writers to feature here. Send us a submission and we'll be in touch!

Send your Writing!

Like what you see?

Get more Knowledge Pathway content like this delivered directly to your inbox. Unsubscribe at any time.